Research Coordination and Promotion Service. National Institute of Health (ISS)
💊 AI and Computational Models for Drug Discovery and Target Identification Listening to Dr. Giedre Kvedaraviciene at the 1st EP PerMed Implementation of Personalised Medicine School – “Data-Driven Research and Implementation” was both insightful and thought-provoking. She highlighted how AI and computational models are reshaping drug discovery and development, offering real opportunities to accelerate timelines, reduce costs, and enhance target identification—ultimately moving us closer to truly personalised therapies. With almost 30% of the world’s data now generated by the healthcare sector, we are surrounded by an unprecedented wealth of information. Yet, unlocking its value requires not only advanced tools but also a shared vision of responsible innovation. Dr. Kvedaraviciene also reminded us of the regulatory complexities ahead: the overlap between the AI Act and the Medical Device Regulation (MDR), and the differences in risk management, dataset governance, and validation standards across regions. These challenges underscore the importance of collaboration between scientists, regulators, and policymakers to ensure safe and ethical progress. As AI continues to advance, keeping patient benefit and trust at the centre will remain essential. #PersonalisedMedicine #AIinHealthcare #DrugDiscovery #EPPerMed #HealthInnovation